Sanofi and radioligand partner Orano Med reported Phase 2 results for AlphaMedix (lead-212 payload) in gastroenteropancreatic neuroendocrine tumors (GEP‑NETs), meeting primary endpoints for overall response rate and demonstrating a manageable safety profile. The readout covers 61 patients including prior Lutathera recipients and sets the dossier for regulatory discussions in Europe and the U.S. Sanofi acquired the asset after a nine-figure upfront and now says the data will underpin conversations with health authorities and potential filings. Orano Med highlighted that the AlphaMedix-02 results validate lead‑212 alpha-emitter platforms and could broaden targeted alpha therapy applications across rare tumors. The partners will present detailed datasets at an upcoming oncology congress.